[The changes of gene expression in multiple myeloma treated with thalidomide].

Article Details

Citation
Copy to clipboard

Zhang HB, Chen SL, Liu JZ, Xiao B, Chen ZB, Wang HJ

[The changes of gene expression in multiple myeloma treated with thalidomide].

Zhonghua Nei Ke Za Zhi. 2003 May;42(5):300-2.

PubMed ID
12882707 [ View in PubMed
]
Abstract

OBJECTIVE: To investigate the effect of thalidomide on bone marrow cells gene expression in multiple myeloma (MM) patients with suppression subtractive hybridization (SSH) and explore the molecular mechanism of thalidomide therapy for MM. METHODS: In a MM patient receiving thalidomide therapy and bone marrow cell from himself, total RNA extraction, mRNA isolation and cDNA synthesis were carried out respectively with routine procedures. SSH were performed in A and B group respectively. The subtracted cDNA was selectively amplified by suppression PCR. The product was inserted into T vector, and then transfected into the competent host JM109. So two subtractive libraries were constructed. After blue-white screening, colonies were selected and plasmids extracted. Homologous comparation was conducted in GenBank. RESULTS: In group A, seven clones were isolated, including ribosomal protein L19 (HUMAN), IgG lambda chain v-v region (HUMAN), contains Alu repetitive element, NADH-ubiquinone oxidoreductase chain 2, elongation factor 1-gamma, human beta globin region, and 40S ribosomal protein S4 (HUMAN). In group B, six clones were isolated, including cytochrome B, up-regulated by 1,25-dihydroxyvitamin D(3) (VDUP1), NADH- ubiquinone oxidoreductase 20 Kd subunit, mu-calpain large subunit, tumor protein, translationally-controlled 1 (TPT1) and COATOMER alpha subunit. CONCLUSION: Thalidomide induces apoptosis and antiangiogenesis by down-regulating some genes and up-regulating some others genes.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
NADHNADH-ubiquinone oxidoreductase chain 2ProteinHumans
Unknown
Binder
Details